Tack CJ, Jacob S, Desouza C, et al. - In this post hoc analysis of the LEADER trial involving 9,340 patients, researchers offered long-term safety and effectiveness data for glucagon-like peptide-1 receptor agonist (GLP-1RA) and insulin in combination. Study participants were randomized 1:1 to liraglutide (up to 1.8 mg, as tolerated) or placebo, plus standard of care treatment, and followed for 3.5 years to 5 years. According to findings, adding liraglutide to insulin treatment for type 2 diabetes patients at high cardiovascular (CV) risk improved glycemic control, decreased body weight, and insulin need for at least 36 months and maintained CV safety without increasing the risk of severe hypoglycemia. These findings favor the combined therapy with liraglutide and insulin.